Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo. Wegovy (semaglutide) is not recommended during pregnancy. UK clinical guidance is clear on this: the medicine should be stopped before trying to conceive, and it must not be used while pregnant or breastfeeding. If you discover you are pregnant while taking it, the right step is to stop immediately and speak to your GP or midwife. This is not a grey area. There is no licensed dose, trimester exception, or clinical scenario in which continuing Wegovy through pregnancy is advised. That fact is worth knowing plainly before anything else on this page.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The short answer is no, and it is not a close call. Wegovy's licence specifically excludes pregnancy. Animal reproductive toxicity studies showed developmental effects at exposures relevant to human therapeutic use, and robust human pregnancy safety data simply does not exist yet. When evidence is absent for a prescription medicine in a vulnerable population, the precautionary position is the correct one, and UK regulators, Novo Nordisk, and prescribing guidance all point the same way.
One misconception that comes up occasionally is the idea that because Wegovy helps with conditions linked to pregnancy complications (such as raised BMI or blood pressure) continuing it might be protective. It is an understandable line of thought, but it is not supported by the evidence or the licence. Gestational weight management is handled through dietitian-led nutrition support, specialist obstetric teams and close monitoring, not GLP-1 receptor agonists. The relationship between Wegovy and pregnancy is something our clinical team sees questions about regularly; the answer has not changed.
If you are currently pregnant and have been taking semaglutide in any form, stop now and speak to your GP or midwife today. They can advise on foetal monitoring and any follow-up needed. Reporting the exposure via the MHRA Yellow Card scheme also contributes to the safety data that will inform future guidance.
Planning ahead makes a real difference here. The question of fertility and Wegovy is worth separating into two distinct parts: contraception during treatment, and the wash-out period before trying to conceive.
During treatment, effective contraception is recommended. For women taking the oral contraceptive pill alongside a GLP-1 medicine, there is an additional consideration: semaglutide slows gastric emptying, which can theoretically affect how reliably the pill is absorbed. Adding a barrier method during this time is a sensible precaution, discuss the specifics with your prescriber or GP, who can advise based on your full picture. NHS guidance on weight-management injections addresses this directly.
When you are ready to try for a baby, do not simply stop Wegovy and assume the medicine has cleared your system overnight. Speak to your prescriber first about timing. A planned wash-out period before conception is the recommended approach; the exact duration is a clinical decision. Stopping at the right time, with support, is safer than stopping abruptly without guidance.
Pausing a medicine that has been working raises a fair concern: will the weight come back? For many people, some weight regain does occur when GLP-1 treatment stops, and pregnancy is not a short window. This is worth discussing honestly with your GP or an obesity specialist well before you try to conceive, so you can plan realistic nutrition and activity support for the pregnancy period.
The NHS medicines guidance on semaglutide confirms that Wegovy is not suitable during pregnancy, and clinical guidelines recommend working with your healthcare team to manage weight through the pregnancy and postpartum period using evidence-based lifestyle approaches. A dietitian referral is often the most useful step. After delivery and once breastfeeding is complete, returning to treatment is a conversation you can have with a prescriber at that point, including through a service like ours, if private treatment fits your circumstances.
The postpartum period can also bring its own challenges around weight, sleep and appetite. Our clinical team reviews every consultation individually, so if you return to treatment after pregnancy, that context is considered properly.
For any of the scenarios above, the right people are your GP, your midwife (if you are already pregnant), and your prescriber if you are on active treatment. These are not questions to resolve through a web search alone. The details (timing, contraception choices, wash-out duration, monitoring after unintended exposure) require a clinical conversation about your specific situation.
If you are thinking about Wegovy for weight management and pregnancy is somewhere in your plans, it is worth raising that proactively at consultation. There is no single answer that fits every timeline, and a prescriber who knows the full picture can give guidance that actually applies to you. You can read more about semaglutide and pregnancy more broadly, or explore what weight-loss treatment options look like across the board. We also have dedicated guidance covering whether you can take Wegovy while pregnant and a separate page addressing what to do if you are already pregnant and using Wegovy, both of which go into further detail on these specific situations. If you have further questions before starting a consultation, our FAQs cover the most common ones.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.